Eli Lilly and Company income statement & cash flow
In the fiscal year ended Dec 31, 2025, Eli Lilly and Company reported net income of $20.64B on revenue of $65.18B. Operating cash flow was $16.81B.
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
| Net income | $2.74B | −$204.10M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B |
| Diluted EPS | $2.58 | −$0.19 | $3.13 | $8.89 | $6.79 | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Operating cash flow | $4.85B | $5.62B | $5.52B | $4.84B | $6.50B | $7.37B | $7.59B | $4.24B | $8.82B | $16.81B |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | — | 31.7% |
| Dec 2024 | — | — | 23.5% |
| Dec 2023 | — | — | 15.4% |
| Dec 2022 | — | — | 21.9% |
| Dec 2021 | — | — | 19.7% |
Source: SEC EDGAR XBRL company facts for CIK 59478 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.